Repository logo
 
Publication

Nanostructured lipid carriers enriched hydrogels for skin topical administration of quercetin and omega-3 fatty acid

dc.contributor.authorLúcio, Marlene
dc.contributor.authorGiannino, Nicole
dc.contributor.authorBarreira, Sérgio
dc.contributor.authorCatita, José
dc.contributor.authorGonçalves, Hugo
dc.contributor.authorRibeiro, Artur
dc.contributor.authorFernandes, Eduarda
dc.contributor.authorCarvalho, Isabel
dc.contributor.authorPinho, Hugo
dc.contributor.authorCerqueira, Fátima
dc.contributor.authorBiondi, Marco
dc.contributor.authorLopes, Carla Martins
dc.date.accessioned2024-01-30T12:26:23Z
dc.date.available2024-01-30T12:26:23Z
dc.date.issued2023
dc.description.abstractChronic skin exposure to external hostile agents (e.g., UV radiation, microorganisms, and oxidizing chemicals) may increase oxidative stress, causing skin damage and aging. Because of their well-known skincare and protective benefits, quercetin (Q) and omega-3 fatty acids (ω3) have attracted the attention of the dermocosmetic and pharmaceutical sectors. However, both bioactives have inherent properties that limit their efficient skin delivery. Therefore, nanostructured lipid carriers (NLCs) and enriched PFC® hydrogels (HGs) have been developed as a dual-approach vehicle for Q and/or ω3 skin topical administration to improve bioactives’ stability and skin permeation. Two NLC formulations were prepared with the same lipid composition but differing in surfactant composition (NLC1—soy lecithin and poloxamer 407; NLC2—Tween® 80 and dioctyl sodium sulfosuccinate (DOSS)), which have an impact on physicochemical properties and pharmaceutical and therapeutic performance. Despite both NLCs presenting high Q loading capacity, NLC2`s physicochemical properties make them more suitable for topical skin administration and ensure longer colloidal stability. Additionally, NLC2 demonstrated a more sustained Q release, indicating higher bioactive storage while improving permeability. The occlusive effect of NLCs-enriched HGs also has a positive impact on skin permeability. Q-loaded NLC2, with or without ω3, -enriched HGs demonstrated efficacy as antioxidant and photoprotective formulations as well as effective reduction in S. aureus growth, indicating that they constitute a promising approach for topical skin administration to prevent skin aging and other damaging cutaneous processes.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citation: Lúcio, M.; Giannino, N.; Barreira, S.; Catita, J.; Gonçalves, H.; Ribeiro, A.; Fernandes, E.; Carvalho, I.; Pinho, H.; Cerqueira, F.; et al. Nanostructured lipid carriers enriched hydrogels for skin topical administration of quercetin and omega-3 fatty acid. Pharmaceutics 2023, 15, 2078. https://doi.org/ 10.3390/pharmaceutics15082078pt_PT
dc.identifier.doi10.3390/pharmaceutics15082078pt_PT
dc.identifier.eissn1999-4923
dc.identifier.urihttp://hdl.handle.net/10284/12622
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.subjectQuercetinpt_PT
dc.subjectOmega-3 fatty acidspt_PT
dc.subjectSkin topical administrationpt_PT
dc.subjectNanostructured lipid carriers (NLCs)pt_PT
dc.subjectAntioxidantpt_PT
dc.subjectPhotoprotectivept_PT
dc.subjectAntimicrobial effectpt_PT
dc.titleNanostructured lipid carriers enriched hydrogels for skin topical administration of quercetin and omega-3 fatty acidpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue8pt_PT
oaire.citation.startPage2078pt_PT
oaire.citation.titlePharmaceuticspt_PT
oaire.citation.volume15pt_PT
person.familyNameBarreira
person.familyNameMorais Catita
person.familyNameCerqueira
person.familyNameLopes
person.givenNameSérgio
person.givenNameJose Antonio
person.givenNameFátima
person.givenNameCarla
person.identifierJose Catita
person.identifier812695
person.identifier.ciencia-id4514-45D3-DC11
person.identifier.ciencia-idB41E-3287-E706
person.identifier.ciencia-idCF14-52ED-5DA0
person.identifier.ciencia-id901D-160C-633E
person.identifier.orcid0000-0001-5956-7501
person.identifier.orcid0000-0001-7270-5702
person.identifier.orcid0000-0003-4513-4654
person.identifier.orcid0000-0001-5080-032X
person.identifier.ridM-7557-2013
person.identifier.ridM-4689-2016
person.identifier.scopus-author-id55812422900
person.identifier.scopus-author-id6507275921
person.identifier.scopus-author-id6603346911
person.identifier.scopus-author-id26649517700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationdbe45ee6-efba-417e-92ef-53145e55db29
relation.isAuthorOfPublication24bb2971-32ae-429b-b397-145dacb66a5a
relation.isAuthorOfPublication2705e35c-97f6-4de2-bbf1-d680342760e9
relation.isAuthorOfPublicationd2a48cfe-9258-4916-99be-bbcb710f6605
relation.isAuthorOfPublication.latestForDiscoveryd2a48cfe-9258-4916-99be-bbcb710f6605

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lúcio et al_ Pharmaceutics _ 2023.pdf
Size:
2.72 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: